Dynavax Technologies (DVAX)
(Real Time Quote from BATS)
$11.80 USD
-0.08 (-0.67%)
Updated May 23, 2024 11:11 AM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Brokerage Reports
Dynavax Technologies Corporation [DVAX]
Reports for Purchase
Showing records 81 - 100 ( 121 total )
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of April 1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Earnings Uneventful; Awaiting BLA Filing In May; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
FDA and DVAX Agree to an Expanded Population for HEPLISAV in Pre-BLA Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of January 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of January 8
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Updating Model Following Milestone Payments from GSK and AZN; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of November 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Completes $64.5 Million Financing; Lowering FV to $5 from $6 on Dilution; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Reports Top-Line Success in Phase III CKD Study; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
ACIP Vote in Favor of HBV Vaccination of Diabetics Adds to HEPLISAV Market Potential
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
GSK Alliance Expands to Include Another TLR Target; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
ACIP Vote on HBV Vaccination for Diabetics Scheduled for October 25; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Additional Subset Data Demonstrates HEPLISAV Efficacy in Diabetic Patients
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Receives $3M Milestone Payment for Advancing AZD1419 into Clinical Development for Asthma
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
HEPLISAV ITT Data Analysis Confirms Strong Efficacy; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
No Surprises in HEPLISAV Data Presentation at ICAAC; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Life Sciences MAC Best Ideas Conference - New York City - August 16 & 17, 2011 Day 2 - Key Takeaways
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Topline Phase III HEPLISAV Data and Q2:2011 Financials
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D